Daniel O'Connell is Chief Executive Officer of Acumen Pharmaceuticals, Inc. (ABOS). The company reported total compensation of $1,863,567 for fiscal year 2025.
| Salary | $646,354 |
|---|---|
| Bonus | $0 |
| Stock awards | $412,482 |
| Option awards | $478,338 |
| Non-equity incentive plan | $305,725 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $20,668 |
| Total | $1,863,567 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Acumen Pharmaceuticals, Inc. filed April 23, 2026, accession 0001628280-26-026870.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel O'Connell this page | Chief Executive Officer | $1,863,567 |
| Jim Doherty | President and Chief Development Officer | $1,012,859 |
| Matthew Zuga | Chief Financial Officer and Chief Business Officer | $948,789 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Acumen Pharmaceuticals, Inc. compensation brief.
Daniel O'Connell's compensation sits inside Acumen Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.